Prot #KRT-232-102: A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Project: Research project

Project Details

StatusFinished
Effective start/end date4/15/19 → 4/15/22

Funding

  • PRA Health Sciences (Prot #KRT-232-102 // Prot #KRT-232-102)
  • Kartos Therapeutics, Inc. (Prot #KRT-232-102 // Prot #KRT-232-102)